{
  "BD1.AX": {
    "city": "South Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "BARD1 Life Sciences Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BARD1 LIFE FPO",
    "state": "WA",
    "summary": "BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.",
    "website": "http://www.bard1.com",
    "zipcode": "3168"
  },
  "CTE.AX": {
    "city": "South Granville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Cryosite Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CRYOSITE FPO",
    "state": "NSW",
    "summary": "Cryosite Limited engages in the supply chain logistics and management of pharmaceutical products used in clinical trials, and biological materials in Australia. It operates in two segments, Clinical Trials & Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials & Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, and biological storage services to the clinical trial and research industry. The Cord Blood and Tissues Storage segment offers long term storage for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. Cryosite Limited was founded in 1999 and is based in South Granville, Australia.",
    "website": "http://www.cryosite.com",
    "zipcode": "2142"
  },
  "DU8.F": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GENETIC TEC.",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "DU8S.F": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENETIC TECHS ADR/600",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "EGQ.F": {
    "city": "South Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "BARD1 Life Sciences Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BARD1 LIFE SCIENCES",
    "state": "WA",
    "summary": "BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.",
    "website": "http://www.bard1.com",
    "zipcode": "3168"
  },
  "GENE": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Genetic Technologies Ltd",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "GSS.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Signatures Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENETICSIG FPO",
    "state": "NSW",
    "summary": "Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based products for detection of infectious diseases under EasyScreen brand name. It also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. Genetic Signatures Limited was founded in 2001 and is headquartered in Sydney, Australia.",
    "website": "http://www.geneticsignatures.com",
    "zipcode": "2042"
  },
  "GTG.AX": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENE TECH FPO",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "IDX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Integral Diagnostics Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INTEG DIAG FPO",
    "state": "VIC",
    "summary": "Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company provides its services through 64 radiology clinics, including 20 hospital sites. Integral Diagnostics Limited was incorporated in 2008 and is headquartered in Melbourne, Australia.",
    "website": "http://www.integraldiagnostics.com.au",
    "zipcode": "3000"
  },
  "L2H.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Lifespot Health Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIFESPOT HEALTH LTD.",
    "state": "VIC",
    "summary": "Lifespot Health Ltd provides diagnostic systems and delivery platforms to healthcare enterprises in Australia. The company is developing the BodyTel System that integrates multiple sensors for capturing diagnostic information for additional diseases; Seng-Vital, a Bluetooth enabled vaporizer and health platform designed for the use of medical cannabis; and FeverTel, a dual mode digital thermometer to record and track family's symptoms. Lifespot Health Ltd was incorporated in 2016 and is based in Melbourne, Australia.",
    "website": "http://www.lifespot-health.com",
    "zipcode": "3000"
  },
  "LSH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Lifespot Health Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIFESPOT FPO",
    "state": "VIC",
    "summary": "Lifespot Health Ltd provides diagnostic systems and delivery platforms to healthcare enterprises in Australia. The company is developing the BodyTel System that integrates multiple sensors for capturing diagnostic information for additional diseases; Seng-Vital, a Bluetooth enabled vaporizer and health platform designed for the use of medical cannabis; and FeverTel, a dual mode digital thermometer to record and track family's symptoms. Lifespot Health Ltd was incorporated in 2016 and is based in Melbourne, Australia.",
    "website": "http://www.lifespot-health.com",
    "zipcode": "3000"
  },
  "MIS.F": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Monash IVF Group Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MONASH IVF GROUP LTD",
    "state": "VIC",
    "summary": "Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnosis and treatment of infertility, fertility research and treatment services, tertiary level prenatal diagnostic services, low intervention IVF services, and diagnostic ultrasound services. Monash IVF Group Limited was incorporated in 2014 and is based in Richmond, Australia.",
    "website": "http://www.monashivfgroup.com.au",
    "zipcode": "3121"
  },
  "MVF.AX": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Monash IVF Group Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MONASH IVF FPO",
    "state": "VIC",
    "summary": "Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnosis and treatment of infertility, fertility research and treatment services, tertiary level prenatal diagnostic services, low intervention IVF services, and diagnostic ultrasound services. Monash IVF Group Limited was incorporated in 2014 and is based in Richmond, Australia.",
    "website": "http://www.monashivfgroup.com.au",
    "zipcode": "3121"
  },
  "RHY.AX": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Rhythm Biosciences Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RHYTHM BIO FPO",
    "state": "VIC",
    "summary": "Rhythm Biosciences Limited engages in developing and commercializing medical diagnostics technology in Australia and internationally. It is developing ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.",
    "website": "http://www.rhythmbio.com",
    "zipcode": "3010"
  },
  "TDLAF": {
    "city": "Greenslopes",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "TBG Diagnostics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TBG DIAGNOSTICS LTD",
    "state": "QLD",
    "summary": "TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.",
    "website": "http://www.tbgbio.com",
    "zipcode": "4120"
  },
  "WFL.AX": {
    "city": "Leederville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Wellfully Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "WELLFULLYL FPO",
    "state": "WA",
    "summary": "Wellfully Limited develops dermaportation and enhanced transdermal polymer technologies for use in the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors in Australia. The company provides partnering services and product solutions for technologies in transdermal and intra-dermal drug delivery; therapeutic and dermatological skincare; cosmetic and non-medicinal active ingredient; oral health; haircare solutions utilizing enhanced brushes and applicators; high penetration surface hygiene technologies; fabric and carpet cleaning technologies; and industrial surface interface systems. It offers various technology platforms, such as Static Micro-arrays, a film based micro-array technology for patches, masks, dressings, and other topical applications; and Field in Motion Micro-arrays, a magnetic micro-array film for use in brushes, applicators, and wipes; Dermaportation, a product development platform for a range of commercial applications; eSkin, a multi-product delivery system that offers a range of product-specific, time-varying magnetic fields for enhanced delivery of multiple formulations; and measured dose delivery devices and packaging solutions. The company was formerly known as OBJ Limited and changed its name to Wellfully Limited in September 2020. Wellfully Limited was founded in 2004 and is based in Leederville, Australia.",
    "website": "http://www.wellfully.net",
    "zipcode": "6007"
  }
}
